Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target?


Journal

The international journal of biochemistry & cell biology
ISSN: 1878-5875
Titre abrégé: Int J Biochem Cell Biol
Pays: Netherlands
ID NLM: 9508482

Informations de publication

Date de publication:
01 2020
Historique:
received: 14 10 2019
revised: 14 11 2019
accepted: 21 11 2019
pubmed: 26 11 2019
medline: 6 10 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

The O subfamily of forkhead (FoxO) 1 is a crucial regulator of cell metabolism in several tissues, including the heart, where it is involved in cardiac regulation of glucose and lipid metabolic pathways, and endothelium, controlling the levels of some relevant biomarkers in atherosclerotic process. Despite the growing understanding of FoxO1 biology, the metabolic consequences of FoxO1 modifications and its implication in CVD, atherosclerosis and T2DM are still not incompletely described. In this review we discuss how FoxO1 affects cardiovascular pathophysiology and which of its effects should be restrained or enhanced to preserve endothelial and heart functions.

Identifiants

pubmed: 31765819
pii: S1357-2725(19)30236-5
doi: 10.1016/j.biocel.2019.105659
pii:
doi:

Substances chimiques

FOXO1 protein, human 0
Forkhead Box Protein O1 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105659

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Rossella Menghini (R)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Viviana Casagrande (V)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Giulia Iuliani (G)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Stefano Rizza (S)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy; Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy.

Maria Mavilio (M)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy.

Marina Cardellini (M)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy; Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy.

Massimo Federici (M)

Laboratory of Molecular Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Italy; Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy. Electronic address: federicm@uniroma2.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH